1117 related articles for article (PubMed ID: 12691470)
1. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
Seeff LB; Hoofnagle JH
Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
[TBL] [Abstract][Full Text] [Related]
2. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
3. Consensus guidelines for the management of hepatitis C infection.
Consensus Guidelines Committee for the Management of Hepatitis C Infection
Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
[TBL] [Abstract][Full Text] [Related]
4. Ribavirin in the treatment of hepatitis C.
Abonyi ME; Lakatos PL
Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
[TBL] [Abstract][Full Text] [Related]
5. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
6. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
Bird SM; Goldberg DJ; Hutchinson SJ
J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
[TBL] [Abstract][Full Text] [Related]
7. Management of hepatitis C virus coinfection in HIV-infected persons.
O'Leary JG; Chung RT
AIDS Read; 2006 Jun; 16(6):313-6, 318-20. PubMed ID: 16795921
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatitis C: a systematic review.
Kohli A; Shaffer A; Sherman A; Kottilil S
JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
[TBL] [Abstract][Full Text] [Related]
9. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users.
Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M
J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710
[TBL] [Abstract][Full Text] [Related]
11. Management issues in chronic viral hepatitis: hepatitis C.
Sievert W
J Gastroenterol Hepatol; 2002 Apr; 17(4):415-22. PubMed ID: 11982722
[TBL] [Abstract][Full Text] [Related]
12. Surveillance for acute viral hepatitis - United States, 2007.
Daniels D; Grytdal S; Wasley A;
MMWR Surveill Summ; 2009 May; 58(3):1-27. PubMed ID: 19478727
[TBL] [Abstract][Full Text] [Related]
13. Diagnosing and treating hepatitis C virus infection.
Schiff ER
Am J Manag Care; 2011 Mar; 17 Suppl 4():S108-15. PubMed ID: 21767067
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
[TBL] [Abstract][Full Text] [Related]
16. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.
Deming P; McNicholl IR
Pharmacotherapy; 2011 Apr; 31(4):357-68. PubMed ID: 21449625
[TBL] [Abstract][Full Text] [Related]
17. Management of hepatitis C in HIV infected and other immunocompromised individuals.
Seth AK
Trop Gastroenterol; 2006; 27(3):111-7. PubMed ID: 17310553
[TBL] [Abstract][Full Text] [Related]
18. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
20. Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men.
Aebi-Popp K; Wandeler G; Salazar-Vizcaya L; Metzner K; Stöckle M; Cavassini M; Hoffmann M; Lüthi A; Suter F; Bernasconi E; Fehr J; Furrer H; Rauch A;
HIV Med; 2018 Jul; 19(6):420-425. PubMed ID: 29573533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]